149606-97-3

Basic information

• Product Name: (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate
• CAS NO: 149606-97-3
• Molecular Formula: C₂₁H₃₁NO₅
• Molecular Weight: 377.47454
• Mol File: 149606-97-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 476.8±20.0 °C(Predicted)
• Appearance: /
• Density: 1.111±0.06 g/cm3(Predicted)
• PKA: -2.22±0.40(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate(149606-97-3)
• EPA Substance Registry System: (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate(149606-97-3)

Safety Data

• Hazardous Substances Data: 149606-97-3(Hazardous Substances Data)

Usage

General Description

"(S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate" is a complex chemical compound with the molecular formula C22H31NO5. It is a pyrrolidine derivative that contains a tert-butyl ester group and a benzyloxy substituent. (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate is formed from the reaction of (R)-3-((tert-butoxycarbonyl)amino)-2-methyl-1-oxopropyl benzoate and L-methionine, involving the formation of a new carboxylate and the protection of the amino group of the starting material. It is commonly used in organic synthesis and pharmaceutical research for the development of drugs and biologically active molecules. (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate may have potential medical applications due to its structural features and functional groups.

Upstream product

• 163768-51-2 benzyl (2R,3R,2'S)-3-(N-tert-butoxycarbonyl-2'-pyrrolidinyl)-3-hydroxy-2-methylpropanoate 
• 74-88-4 methyl iodide 
• 133645-51-9 (4R,5S,2'R,3'R,2S)-3-[3'-(N-tert-butoxycarbonyl-2-pyrrolidinyl)-3-hydroxy-2'-methylpropanoyl]-4-methyl-5-phenyl-2-oxazolidinone 
• 120205-50-7 N-Boc-(2R,3R,4S)-dolaproine 
• 100-44-7 benzyl chloride 
• 180715-99-5 (4R,5S,2'R,3'R,2S)-3-[3'-(N-tert-butoxycarbonyl-2-pyrrolidinyl)-3'-methoxy-2'-methylpropanoyl]-4-methyl-5-phenyl-2-oxazolidinone 
• 100-51-6 benzyl alcohol 
• 1369427-40-6 (2R,3R)-3-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionic acid dicyclohexylamine salt 
• 100-39-0 benzyl bromide 
• 69610-41-9 Boc-L-Pro-H 
• 122-63-4 benzyl proprionate 
• 186581-53-3 diazomethane 

Downstream Products

• 474645-27-7 [3H]-Vedotin 

Relevant articles and documents

EFFICIENT PREPARATION OF DOLASTATIN AND AURISTATIN ANALOGS THROUGH A COMMON INTERMEDIATE

Methods for making a dolastatin, auristatin or related compounds comprising the steps of providing a universal dolastatin core of Formula (I) reacting the C-terminal carboxylic acid group with an amine (A) to form an amide bond and reacting the N-terminal amine with a carboxylic acid (CA) to form an amide bond, wherein the steps can be performed in either order. Also provided are an isolated salt of the universal dolastatin core for use in preparation of dolastatins, auristatins and related compounds. Also provided are a number of intermediates and process steps which are useful for the preparation of high purity dolastatin core and high purity dolastatin and auristatin compounds.

NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME

The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.